BioCentury | Nov 20, 2014
Tools & Techniques

HemoShear's human touch

HemoShear LLC 's October announcement that a new application of its in vitro tissue modeling platform to tumors reproduces the human response to cisplatin means the company could soon tap into business from drug developers...
BioCentury | Aug 7, 2014
Cover Story

Dyeing to diagnose preeclampsia

Although there is widespread agreement on the need for a better way to diagnose preeclampsia, few companies have pursued new tests because finding specific markers has been difficult. A Yale-led group has found dye-binding aggregates...
BioCentury | Sep 12, 2013
Cover Story

TLR4 signaling in allergic asthma

Baylor College of Medicine researchers have uncovered a pathway in allergic asthma that opens up the potential for developing therapeutics that target the causes of the disease rather than just its symptoms. 1 The team...
BioCentury | Jun 20, 2013
Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Atherosclerosis Dickkopf homolog 1 (DKK1) Cell culture studies suggest inhibiting DKK1 could help treat atherosclerosis. Endothelial-to-mesenchymal transition contributes to calcification and fibrosis in atherosclerosis....
BioCentury | Oct 4, 2012
Cover Story

Slipping past P glycoprotein

NIH researchers have shown that sphingosine 1-phosphate receptor agonists such as Novartis AG 's Gilenya fingolimod could transiently reduce P glycoprotein -mediated drug efflux and enhance drug delivery to the brain. 1 The group at...
BioCentury | Apr 12, 2012
Targets & Mechanisms

DEL1: taking the bite out of periodontitis

An international team of researchers has used the endothelial protein DEL1 to treat periodontitis in mice. 1 Despite the therapeutic angle, the near-term utility of DEL1 is more likely to be as a diagnostic and...
BioCentury | Sep 29, 2011
Tools & Techniques

Tissue factor-activated prodrugs

A team at The Scripps Research Institute has designed a prodrug of doxorubicin that is activated by components of the tissue factor coagulation cascade present in high concentrations in the tumor microenvironment, thus avoiding off-target...
BioCentury | Sep 1, 2011
Cover Story

IL-20's osteoporosis connection

A group of Taiwanese researchers has shown that an antibody against IL-20 helped treat osteoporosis in mice. 1 The findings have grabbed the attention of Novo Nordisk A/S , which has an anti-IL-20 mAb in Phase...
BioCentury | Jun 9, 2011
Targets & Mechanisms

Short-circuiting DCs in atherosclerosis

A team of European researchers has identified a way to target proinflammatory dendritic cells that contribute to atherosclerotic plaques in mice. 1 Carolus Therapeutics Inc. has a nonexclusive option to license the findings and believes...
BioCentury | Apr 14, 2011
Strategy

sanofi rolls the bones

sanofi-aventis Group has seized an early stage opportunity that opened up when Biogen Idec Inc. recently refocused on neurology, by picking up an obesity and type 2 diabetes program centered on osteocalcin that was previously...
Items per page:
1 - 10 of 18
BioCentury | Nov 20, 2014
Tools & Techniques

HemoShear's human touch

HemoShear LLC 's October announcement that a new application of its in vitro tissue modeling platform to tumors reproduces the human response to cisplatin means the company could soon tap into business from drug developers...
BioCentury | Aug 7, 2014
Cover Story

Dyeing to diagnose preeclampsia

Although there is widespread agreement on the need for a better way to diagnose preeclampsia, few companies have pursued new tests because finding specific markers has been difficult. A Yale-led group has found dye-binding aggregates...
BioCentury | Sep 12, 2013
Cover Story

TLR4 signaling in allergic asthma

Baylor College of Medicine researchers have uncovered a pathway in allergic asthma that opens up the potential for developing therapeutics that target the causes of the disease rather than just its symptoms. 1 The team...
BioCentury | Jun 20, 2013
Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Atherosclerosis Dickkopf homolog 1 (DKK1) Cell culture studies suggest inhibiting DKK1 could help treat atherosclerosis. Endothelial-to-mesenchymal transition contributes to calcification and fibrosis in atherosclerosis....
BioCentury | Oct 4, 2012
Cover Story

Slipping past P glycoprotein

NIH researchers have shown that sphingosine 1-phosphate receptor agonists such as Novartis AG 's Gilenya fingolimod could transiently reduce P glycoprotein -mediated drug efflux and enhance drug delivery to the brain. 1 The group at...
BioCentury | Apr 12, 2012
Targets & Mechanisms

DEL1: taking the bite out of periodontitis

An international team of researchers has used the endothelial protein DEL1 to treat periodontitis in mice. 1 Despite the therapeutic angle, the near-term utility of DEL1 is more likely to be as a diagnostic and...
BioCentury | Sep 29, 2011
Tools & Techniques

Tissue factor-activated prodrugs

A team at The Scripps Research Institute has designed a prodrug of doxorubicin that is activated by components of the tissue factor coagulation cascade present in high concentrations in the tumor microenvironment, thus avoiding off-target...
BioCentury | Sep 1, 2011
Cover Story

IL-20's osteoporosis connection

A group of Taiwanese researchers has shown that an antibody against IL-20 helped treat osteoporosis in mice. 1 The findings have grabbed the attention of Novo Nordisk A/S , which has an anti-IL-20 mAb in Phase...
BioCentury | Jun 9, 2011
Targets & Mechanisms

Short-circuiting DCs in atherosclerosis

A team of European researchers has identified a way to target proinflammatory dendritic cells that contribute to atherosclerotic plaques in mice. 1 Carolus Therapeutics Inc. has a nonexclusive option to license the findings and believes...
BioCentury | Apr 14, 2011
Strategy

sanofi rolls the bones

sanofi-aventis Group has seized an early stage opportunity that opened up when Biogen Idec Inc. recently refocused on neurology, by picking up an obesity and type 2 diabetes program centered on osteocalcin that was previously...
Items per page:
1 - 10 of 18